13.91 USD
▼-0.65-4.46%
盘后 13.92 +0.07%
2026-09-15
市值
$810.43M
市盈率
—
EPS
-0.83
股息率
—
52 周区间
1.54 – 18.33
成交量
1.55M
Beta
0.10
目标价
27.57
52W 低 1.5452W 高 18.33
价格走势
公司简介
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ...